Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25686471 | 0.84 | LMNA (0.47) | HSD11B1ADRA2BSMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL2080679 | 0.83 | NR1H3 (0.56) | SMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL18156890 | 0.80 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CMAPT | |
| SCHEMBL10165226 | 0.79 | HSD11B1 (0.59) | HSD11B1NR1H2NR1H3 | |
| SCHEMBL13798571 | 0.79 | MAPT (0.40) | ADRA2AADRA2BADRA2CPDK1PDK2 | |
| SCHEMBL10721177 | 0.79 | ESR1 (0.45) | ADRA2AADRA2BADRA2CSMN1; SMN2MAPT | |
| SCHEMBL21087226 | 0.79 | KIF11 (0.53) | HSD11B1PDK1PDK2PDK3PDK4 | |
| SCHEMBL1797711 | 0.78 | KIF11 (0.52) | ADRA2AADRA2BADRA2CSMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL28869473 | 0.76 | KIF11 (0.50) | ADRA2AADRA2BADRA2CSMN1; SMN2MAPT | |
| Iodide SCHEMBL29229874 | 0.76 | KIF11 (0.50) | ADRA2AADRA2BADRA2CSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | ORPHAGEN PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9657053-B2 | Modulators of retinoid-related orphan receptor gamma | Orphagen Pharmaceuticals (US) | 2017-05-23 | — | — | US | disclosed |
| US-20130150333-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | Orphagen Pharmaceuticals (US) | 2013-06-13 | — | — | US | disclosed |
| US-8389739-B1 | Modulators of retinoid-related orphan receptor gamma | Orphagen Pharmaceuticals (US) | 2013-03-05 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| EP-1907357-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150333-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RORC, RORB, RORA | HSD11B1 229/4885ADRA2A 629/4885ADRA2B 415/4885 |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | ARSA, SULT2A1, SULT1A1 | HSD11B1 680/4885ADRA2A 247/4885ADRA2B 394/4885 |
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RORC, RORB, RORA | HSD11B1 229/4885ADRA2A 629/4885ADRA2B 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.